Literature DB >> 7946051

Th1 versus Th2 responses in AIDS.

S Romagnani1, E Maggi.   

Abstract

During the past two years, a simple theory that seeks to explain what causes the progression of HIV-infected individuals to AIDS has been gaining support. The theory holds that HIV-infected people switch from a T-helper type 1 (Th1) to a T-helper type 2 (Th2) state as the disease progresses. However the experimental data do not support the concept that a Th1/Th2 switch occurs in the majority of HIV-infected subjects, although it is conceivable that HIV-infected individuals who mount sustained and chronic Th2-type responses, as a result of allergic disorders and helminthic infestations, may undergo more active HIV replication and therefore progress faster to full-blown disease.

Entities:  

Mesh:

Year:  1994        PMID: 7946051     DOI: 10.1016/0952-7915(94)90150-3

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  14 in total

Review 1.  Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients.

Authors:  Samuele E Burastero; Clara Paolucci; Daniela Breda; Armando Soldarini; Fernanda Dorigatti; Elisa Soprana; Hamid Hasson; Priscilla Biswas; Adriano Lazzarin; Antonella Castagna
Journal:  J Clin Immunol       Date:  2006-04-07       Impact factor: 8.317

3.  Differences in humoral responses to the p24 antigen between Ethiopian and Swedish human immunodeficiency virus type 1-infected patients may suggest influences from a T-helper 2-like phenotype.

Authors:  T Kebede; S Britton; T Fehniger; A Vahlne; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  Th0-like CD4+ T cells protect mice with murine retrovirus-induced immunodeficiency syndrome (MAIDS) against co-infection with Listeria monocytogenes.

Authors:  K Hiromatsu; H Nishimura; K Kimura; Y Aoki; J Usami; N Kobayashi; M Makino; Y Yoshikai
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

5.  Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Authors:  S Sasaki; K Sumino; K Hamajima; J Fukushima; N Ishii; S Kawamoto; H Mohri; C R Kensil; K Okuda
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults.

Authors:  Kayvon Modjarrad; Isaac Zulu; David T Redden; Lungowe Njobvu; H Clifford Lane; Zvi Bentwich; Sten H Vermund
Journal:  J Infect Dis       Date:  2005-08-25       Impact factor: 5.226

7.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

Authors:  R W Tindle; S Croft; K Herd; K Malcolm; A F Geczy; T Stewart; G J Fernando
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

10.  Expression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patients.

Authors:  F Diaz-Mitoma; A Kumar; S Karimi; M Kryworuchko; M P Daftarian; W D Creery; L G Filion; W Cameron
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.